Exploring New Horizons: Promising Clinical Trials for Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) can be an overwhelming diagnosis, but you are not alone, and there are reasons to be hopeful. Every day, advancements are being made in medical research, opening new doors to more effective solutions. If you are seeking options to improve your quality of life, our platform offers an opportunity to access the latest clinical trials in MDS. These studies aim not only to find answers but also to give you the chance to play an active role in your care and in the fight against this disease. Your path to better health could start here.

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
  • United States+1
  • United Kingdom+44
  • Afghanistan (‫افغانستان‬‎)+93
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1
  • Andorra+376
  • Angola+244
  • Anguilla+1
  • Antigua and Barbuda+1
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Ascension Island+247
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1
  • Bahrain (‫البحرين‬‎)+973
  • Bangladesh (বাংলাদেশ)+880
  • Barbados+1
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Eswatini+268
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1
  • Guadeloupe+590
  • Guam+1
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Iran (‫ایران‬‎)+98
  • Iraq (‫العراق‬‎)+964
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Nepal (नेपाल)+977
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • North Korea (조선 민주주의 인민 공화국)+850
  • North Macedonia (Северна Македонија)+389
  • Northern Mariana Islands+1
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Pakistan (‫پاکستان‬‎)+92
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1
  • Saint Lucia+1
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1
  • Tuvalu+688
  • U.S. Virgin Islands+1
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358

Your Birthday


By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.

Compliance and Security Certifications

Massive Bio has onboarded over 160,000 cancer patients to find their clinical trial

Our system connects you to cutting-edge clinical trials, opening up new possibilities for those living with myelodysplastic syndrome. Through our platform, you can access detailed information about clinical trials tailored to every stage of the disease. These trials include new options specifically designed to target myelodysplastic syndrome and its main symptoms. By participating, you have the chance to actively fight the disease alongside us.

The Latest in Myelodysplastic Syndrome Clinical Trials

Our system connects you to cutting-edge clinical trials, opening up new possibilities for those living with myelodysplastic syndrome. Through our platform, you can access detailed information about clinical trials tailored to every stage of the disease. These trials include new options specifically designed to target myelodysplastic syndrome and its main symptoms. By participating, you have the chance to actively fight the disease alongside us.

How Our System Works

By reviewing your medical records and utilizing our AI system, we identify clinical trials you may qualify for. We also provide a concierge service to assist with your smooth transition into these trials. Our team of nurses and doctors manages all aspects of your participation from start to finish. All services are completely free for you and your oncologist.

Understanding the Disease

What is Myelodysplastic Syndrome?

Myelodysplastic syndrome (MDS) is a group of rare blood disorders that primarily affect older adults. In healthy individuals, bone marrow is responsible for producing mature blood cells, including red blood cells, white blood cells, and platelets. In MDS, blood cells do not mature properly and remain in an immature form known as “blasts” within the bone marrow. These blasts accumulate, reducing the number of mature blood cells and impairing their functions. MDS encompasses a spectrum of diseases with varying potential to remain stable or progress to acute myeloid leukemia (AML).

Classification of Myelodysplastic Syndrome

Myelodysplastic Syndrome is classified into two main types:

Primary MDS: This form occurs without a known cause, developing on its own, typically in older adults. It is the most common type of MDS.

Secondary MDS: This type is caused by previous treatments, such as chemotherapy or radiation. Secondary MDS is usually more aggressive and harder to treat than primary MDS.

What are the Common Symptoms of Myelodysplastic Syndrome?

Dizziness: A feeling of lightheadedness or unsteadiness, which can make one feel as though they might faint.

Pale Skin: A lighter-than-usual skin tone.

Frequent Infections: A tendency to get sick more often than usual or to have infections that are difficult to resolve.

Hematomas: Collections of blood outside blood vessels, appearing as bruises under the skin.

Petechiae: Small red or purple spots on the skin, typically caused by bleeding beneath the surface.

Recognizing myelodysplastic syndrome symptoms, such as fatigue, anemia, infections, or bleeding/bruising, is vital for early diagnosis and effective management. Early detection allows timely option, which helps manage symptoms, prevent complications, and improve patient outcomes.

Navigating Complications of Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) can lead to several complications that may impact your daily life. Understanding these complications is crucial for managing the disease effectively and improving your quality of life. Knowing what to watch for can help you and your healthcare team take proactive steps to manage these challenges.

Acute Myeloid Leukemia (AML): As normal bone marrow function decreases, 40-50% of MDS cases may deteriorate into AML, a form of cancer. This transition occurs when blasts (immature blood cells) in the bone marrow exceed 20%.

Severe Anemia: A significant reduction in red blood cells, leading to chronic fatigue, weakness, and shortness of breath.

Thrombocytopenia: A condition characterized by a low platelet count, which can cause easy bruising, frequent nosebleeds, and prolonged bleeding from cuts due to impaired blood clotting.

Neutropenia: A reduction in white blood cells, resulting in an increased risk of infections.

Pancytopenia: A reduction in all three types of blood cells (red blood cells, white blood cells, and platelets).

Myelodysplastic Syndrome Risk Classification

Once MDS is diagnosed, determining the risk classification is crucial. Patient risk status is assessed based on complete blood counts, the proportion of immature cells in the bone marrow, and the type of genetic abnormalities present in bone marrow cells. This classification helps predict disease progression, guides treatment decisions, and provides insight into prognosis.

Very Low Risk: Mild disease with only minor abnormalities in blood counts, and a low chance of developing leukemia.

Low Risk: Blood cell counts are low, causing mild symptoms. The risk of disease progression or developing leukemia is still low, but some treatment may be needed to manage symptoms.

Moderate-Low Risk: More noticeable abnormalities in blood counts, with a moderate risk of disease worsening.

Moderate-High Risk: Significantly low blood counts leading to notable symptoms, with a higher risk of progressing to leukemia. More intensive treatments may be required.

High Risk: Very low blood cell counts with serious abnormalities in the bone marrow, with a high likelihood of progression to AML. Aggressive treatments, such as chemotherapy and bone marrow transplant, are often necessary.

Very High Risk: Severe disease with extremely low blood counts and a high level of abnormal cells in the bone marrow. There is a very high risk of rapidly developing AML, requiring intensive treatment.

Accurate risk classification helps tailor options to specific disease risks, optimizing efficacy and safety for myelodysplastic syndrome patients.

Treated vs. Untreated Myelodysplastic Syndrome

Untreated Myelodysplastic Syndrome: Refers to patients who have been diagnosed but have not yet received any specific treatment. Clinical trials for these patients often focus on novel therapies and combinations to improve initial treatment outcomes and long-term prognosis.

Treated Myelodysplastic Syndrome: Refers to patients who have already undergone treatment but may have experienced disease progression, relapse, or insufficient response. Clinical trials for this group focus on new treatment options for relapsed, refractory, or treatment-intolerant patients.

Relapsed/Refractory vs. Non-Relapsed/Refractory Myelodysplastic Syndrome

Relapsed/Refractory MDS: Refers to MDS that is difficult to control, either returning after treatment (relapsed) or not responding to initial treatment (refractory). Patients with relapsed/refractory MDS typically require different or more aggressive treatments.

Non-Relapsed/Refractory MDS: Refers to MDS that responds well to initial treatment and does not return or worsen afterward. Patients can manage their symptoms and maintain better disease control with standard treatment options.

What are the Current Options for Myelodysplastic Syndrome?

Option for MDS depends on the patient’s clinical risk status, including the likelihood of developing leukemia or remaining stable. By identifying the risk level, physicians can tailor treatments to ensure personalized care and better disease management.

Erythropoiesis-Stimulating Agents: Drugs that stimulate the bone marrow to produce more red blood cells, helping to treat anemia and reduce the need for blood transfusions. These are typically used in patients with low-risk MDS.

Hypomethylating Agents: Medications that inhibit DNA methylation, promoting the production of normal blood cells and reducing abnormal cell growth. These belong to the group of lower-intensity therapies for MDS.

Immunosuppressive Therapy: Drugs that enhance blood cell production by reducing the immune system’s attack on the bone marrow.

IDH Inhibitors: Target mutated IDH proteins, helping to decrease the production of abnormal cells and slow disease progression. These are considered low-intensity therapies.

Chemotherapy: A systemic therapy that targets and kills rapidly dividing abnormal cells, aiming to reduce the number of blasts and prevent progression to leukemia.

Hematopoietic Cell Transplantation: A procedure that replaces diseased bone marrow with healthy donor stem cells, offering a potential cure for MDS, particularly in younger patients.

Supportive Care: Includes treatments like blood transfusions and antibiotics to manage symptoms, improve quality of life, and prevent complications without directly targeting MDS.

Clinical Trials: Research studies that test new options for MDS, providing patients with access to innovative possibilities not yet widely available.

Enhancing Prospects with Genomic Testing

NGS Testing and Clinical Trials

Next-Generation Sequencing (NGS) plays a crucial role in connecting patients with specific genetic changes in their cancer to clinical trials that offer targeted options. This personalized approach helps match you with options that are more likely to be effective for your specific type of cancer, increasing the chances of success in these trials. By using NGS, we can better understand your cancer and find the best options for you.

The genetic mutations, also known as biomarkers, are often related to the disease’s origin. Some common biomarkers associated with myelodysplastic syndrome include:

TP53: A mutated gene that leads to the loss of regulatory functions controlling cell growth, allowing abnormal cells to survive and proliferate. It is associated with poor prognosis and a higher risk of disease progression to leukemia.

SF3B1: A mutated gene that results in defective production of functional proteins. It is linked to a favorable prognosis.

ASXL1: Mutations in this gene cause uncontrolled cell growth and are associated with a worse prognosis and a higher risk of progression to AML.

IDH1/2: Mutations in these genes lead to the production of an abnormal substance that promotes leukemic transformation. These mutations can be targeted by specific IDH inhibitors for treatment.

The Role of Clinical Trials in Myelodysplastic Syndrome

Clinical trials play a crucial role  for several reasons:

Access to Innovative Options: Clinical trials offer individuals the opportunity to access novel possibilities, particularly crucial for serious conditions like myelodysplastic syndrome, where conventional options may be less effective.

Enhancing Outcomes: Participation in clinical trials allows patients to contribute valuable insights that may enhance survival rates and overall well-being for future myelodysplastic syndrome patients.

Hope for the Future: For many individuals dealing with myelodysplastic syndrome, involvement in a clinical trial instills hope, both for their own recovery and for the potential positive impact on future patients.

Comprehensive Medical Attention: Patients enrolled in clinical trials typically receive comprehensive care, with a dedicated team of healthcare providers and researchers closely monitoring their progress.

Promoting Research Advancements: Clinical trials play a pivotal role in advancing research, aiding scientists in understanding the effectiveness of new options and identifying which patients benefit the most.

Dr. Arturo explains:

What Are Clinical Trials?

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.

How Massive Bio Helps Patients With Myelodysplastic Syndrome
1
Consent Signed

Fill out our contact form and sign our consent form

2
Data Collection

We collect your medical records securely

3
Pre Screening

Our expert nurses check clinical trials and contact you

4
Concierge Services

We support you with appointments, travel, and accommodation

Let’s explore your options and bring new hope to your journey.

We offer a quick, easy and FREE way to find myelodysplastic syndrome clinical research opportunities for patients like you. With our unique clinical trial matching system (CTMS) and team specialized in oncology, we can rapidly match you to a clinical research study for those diagnosed with myelodysplastic syndrome.

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
  • United States+1
  • United Kingdom+44
  • Afghanistan (‫افغانستان‬‎)+93
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1
  • Andorra+376
  • Angola+244
  • Anguilla+1
  • Antigua and Barbuda+1
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Ascension Island+247
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1
  • Bahrain (‫البحرين‬‎)+973
  • Bangladesh (বাংলাদেশ)+880
  • Barbados+1
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Eswatini+268
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1
  • Guadeloupe+590
  • Guam+1
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Iran (‫ایران‬‎)+98
  • Iraq (‫العراق‬‎)+964
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Nepal (नेपाल)+977
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • North Korea (조선 민주주의 인민 공화국)+850
  • North Macedonia (Северна Македонија)+389
  • Northern Mariana Islands+1
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Pakistan (‫پاکستان‬‎)+92
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1
  • Saint Lucia+1
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1
  • Tuvalu+688
  • U.S. Virgin Islands+1
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358

Your Birthday


By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.
Frequently asked questions